Skip to main content
Article
Concordance between the Chang and the International Society of Pediatric Oncology (SIOP) ototoxicity grading scales in patients treated with cisplatin for medulloblastoma
Pediatric Blood and Cancer (2014)
  • Johnnie K. Bass, University of Memphis
  • Jie Huang, St. Jude Children's Research Hospital
  • Arzu Onar-Thomas, St Jude Children’s Research Hospital
  • Kay W. Chang, Stanford University
  • Shaum P. Bhagat, University of Memphis
  • Murali Chintagumpala, Texas Children's Hospital
  • Ute Bartels, Hospital for Sick Children, Toronto
  • Sridharan Gururangan, Duke University
  • Tim Hassall, Royal Children's Hospital, Brisbane
  • John A. Heath, Royal Children's Hospital, Melbourne
  • Geoffrey McCowage, Children's Hospital at Westmead, Sydney
  • Richard J. Cohn, Sydney Children's Hospital, Sydney
  • Michael J. Fisher, The Children's Hospital of Philadelphia
  • Giles Robinson, St. Jude Children's Research Hospital
  • Alberto Broniscer, St. Jude Children's Research Hospital
  • Amar Gajjar, St. Jude Children's Research Hospital
  • James G. Gurney, University of Memphis
Abstract
Background
Reporting ototoxicity is frequently complicated by use of various ototoxicity criteria. The International Society of Pediatric Oncology (SIOP) ototoxicity grading scale was recently proposed for standardized use in reporting hearing loss outcomes across institutions. The aim of this study was to evaluate the concordance between the Chang and SIOP ototoxicity grading scales. Differences between the two scales were identified and the implications these differences may have in the clinical setting were discussed.
Procedures
Audiological evaluations were reviewed for 379 patients with newly diagnosed medulloblastoma (ages 3–21 years). Each patient was enrolled on one of two St. Jude clinical protocols that included craniospinal radiation therapy and four courses of 75 mg/m2 cisplatin chemotherapy. The latest audiogram conducted 5.5–24.5 months post-protocol treatment initiation was graded using the Chang and SIOP ototoxicity criteria. Clinically significant hearing loss was defined as Chang grade ≥2a and SIOP ≥2. Hearing loss was considered serious (requiring a hearing aid) at the level of Chang grade ≥2b and SIOP ≥3.
Results
A strong concordance was observed between the Chang and SIOP ototoxicity scales (Stuart's tau-c statistic = 0.89, 95% CI: 0.86, 0.91). Among those patients diagnosed with serious hearing loss, the two scales were in good agreement. However, the scales deviated from one another in classifying patients with less serious or no hearing loss.
Conclusions
Although discrepancies between the Chang and SIOP ototoxicity scales exist primarily for patients with no or minimal hearing loss, the scales share a strong concordance overall.
Pediatr Blood Cancer 2014;61:601–605.
© 2013 Wiley Periodicals, Inc.
Publication Date
April, 2014
DOI
10.1002/pbc.24830
Publisher Statement
This is the Accepted Manuscript of an article that appeared in Pediatric Blood and Cancer, volume 61, issue 4, 2014. The Version of Record is available at http://dx.doi.org/10.1002/pbc.24830
Citation Information
Johnnie K. Bass, Jie Huang, Arzu Onar-Thomas, Kay W. Chang, et al.. "Concordance between the Chang and the International Society of Pediatric Oncology (SIOP) ototoxicity grading scales in patients treated with cisplatin for medulloblastoma" Pediatric Blood and Cancer Vol. 61 Iss. 4 (2014) p. 601 - 605 ISSN: 1545-5017
Available at: http://works.bepress.com/shaum-bhagat/11/